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Adipose tissue is recognized as a pivotal organ in the
development of insulin resistance. This study seeks to
determine the effect of angiotensin receptor blockade (ARB)
on insulin resistance of adipocytes in culture and in a rat
model of type 2 diabetes. Treatment of Otsuka Long-Evans
Tokushima Fatty rats with the ARB L158809 for six months
significantly lowered fasting plasma glucose, cholesterol and
triglyceride levels but led to higher plasma adiponectin
levels. Insulin resistance, measured by an intraperitoneal
glucose tolerance test, of the treated rats was significantly
improved along with an increase in the number of small
differentiated adipocytes; however, epididymal fat mass
decreased. Treatment significantly lowered lipid peroxidation
and MCP-1 expression while increasing adiponectin
production by the adipose tissue. ARB treatment significantly
improved insulin sensitivity and markedly suppressed
AT2-induced oxidative stress, PAI-1 and MCP-1 levels and
NF-jB activation of adipocytes in culture. Treatment
increased adiponectin and PPARc expression along with
intracellular triglyceride levels reflecting differentiation of the
cultured adipocytes. Our study suggests that ARB treatment
improves insulin resistance by modification of adipose tissue
thereby blunting the development of diabetes.
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Recent hypertension trials have reported a lower incidence
of diabetes mellitus among patients treated with renin-
angiotensin system (RAS) inhibitor when compared with
other classes of antihypertensive medications.1–4 Although
these studies were mostly performed with patients with
hypertension or congestive heart failure, a 22% relative risk
reduction for new-onset diabetes mellitus was demonstrated
in a meta-analysis of randomized controlled trials, including
75,677 nondiabetic subjects after a mean follow-up period of
4–5 years.5 Furthermore, the activity of RAS is also linked
with the metabolic syndrome.6 Taken together, these findings
suggest that RAS may have an important role in the
development of diabetes mellitus.
Adipocytes have recently attracted attention as dynamic
endocrine cells that produce and secrete various bioactive
molecules that are collectively referred to as adipocytokines,
some of which affect the glucose homeostasis and insulin
resistance of other tissues.7–9 Adipose tissue has now been
targeted as a pivotal organ for the development of insulin
resistance, rather than for its energy storage function. Among
the many adipocytokines, tumor necrosis factor-a (TNF-a),
leptin, plasminogen activator inhibitor-1 (PAI-1), inter-
leukin-6 (IL-6), resistin, visfatin, monocyte chemoattractant
peptide-1 (MCP-1), and adiponectin have been implicated as
active molecules in the development of insulin resistance.7–11
Interestingly, mature adipocytes express all components
of the renin–angiotensin system, including angiotensinogen,
angiotensin-converting enzyme, as well as angiotensin type 1
(AT1) and angiotensin type 2 (AT2) receptors.12 For these
reasons, it can be hypothesized that the antidiabetic effect of
RAS inhibition may derive from the effect of these drugs on
adipocyte function, including the modulation of adipocytokines.
The primary objective of this study was to investigate the
effect of an AT1 receptor antagonist, L158809, on insulin
resistance under the hypothesis that angiotensin receptor
blockade (ARB) may improve insulin resistance through the
modulation of adipose tissues in Otsuka Long–Evans
Tokushima Fatty (OLETF) rats. Additionally, to define the
direct molecular mechanism of ARB, the effects of angiotensin
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2008 International Society of Nephrology
Received 22 November 2007; revised 11 April 2008; accepted 29 April
2008; published online 2 July 2008
Correspondence: Dae R. Cha, Department of Internal Medicine, Korea
University, Ansan-Hospital, 516 Kojan-Dong, Ansan City, Kyungki-Do 425-020,
Republic of Korea. E-mail: cdragn@unitel.co.kr
890 Kidney International (2008) 74, 890–900
and ARB on adipocyte function and the synthesis of adipo-
cytokines were evaluated in cultured murine adipocytes.
RESULTS
Biochemical parameters in experimental animals
Table 1 compares various biochemical parameters among three
experimental groups of rats. The fasting plasma glucose level
was significantly higher in OLETF rats compared with that in
Long–Evans Tokushima Fatty (LETO) rats. Treatment of
OLETF rats with L158809 for 6 months induced a significantly
decreased fasting plasma glucose level. Body weight and
kidney/body weight were also higher in OLETF rats than in
LETO rats. L158809 treatment did not induce a significant
change in body weight or kidney/body weight. Plasma insulin
and c-peptide levels were significantly higher in OLETF rats
than in LETO rats, although the L158809-treated group did not
show a significant difference compared with the OLETF rats.
Although serum creatinine levels and urine volumes were not
different among the three groups, urinary albumin excretion in
the OLETF rats was significantly higher than in the LETO rats.
L158809 treatment significantly reduced urinary albumin
excretion. Systolic blood pressure was greater in OLETF rats
than in LETO rats, and L158809 treatment induced a
significant decrease in systolic blood pressure.
Effect of L158809 on insulin resistance and metabolic
parameters in experimental animals
As shown in Figure 1, improved glucose intolerance after
treatment with L158809 in OLETF rats was confirmed by an
i.p. glucose tolerance test (GTT). Although the basal levels of
fasting blood glucose were slightly lower in the L158809-
treated group, GTT clearly demonstrated improved glucose
intolerance in L158809-treated rats vs OLETF rats. In
accordance with improved glucose intolerance, L158809
treatment significantly decreased plasma total cholesterol
and triglyceride levels (cholesterol, LETO; 113±7.9, OLETF;
147±23, OLETFþ L158809; 100±14, triglyceride, LETO;
39±11, OLETF; 167±19, OLETFþ L158809; 69±21,
Po0.05) (Figure 2a). In addition, plasma adiponectin levels
were decreased in OLETF rats compared with control LETO
rats, and L158809 treatment induced a significant increase in
plasma adiponectin levels (LETO; 11±1.2, OLETF; 8.1±0.2,
OLETFþ L158809; 9.7±0.36, Po0.05) (Figure 2b). How-
ever, the homeostasis model assessment indices (HOMA-IRs)
did not show a significant difference among the three groups
(LETO; 0.65±0.12, OLETF; 0.77±0.11, OLETFþ L158809;
0.69±0.21) (Figure 2c).
Effect of L158809 on histological changes of kidney and
adipose tissue in experimental animals
Figure 3 shows the representative renal pathology in the
experimental groups at the end of the study period. Diabetic
OLETF rats showed more severe glomerulosclerosis when
compared with the LETO rats. Consistent with the marked
attenuation of albuminuria, the glomerulosclerotic index was
significantly improved in the L158809-treatment group.
Next, this study assessed whether the differences in body
weight were related to the alteration in adiposity and to the
L158809-induced phenotypic changes in adipose tissue. As
shown in Figure 4, adipose tissue obtained from epididymal
fat revealed that OLETF rats had larger adipocytes than LETO
rats, and L158809 treatment restored their phenotype to
small differentiated adipocytes (Figure 4a–c). In addition
to these phenotypic changes, epididymal fat mass in OLETF
rats was also significantly higher than in LETO rats, and
the L158809-treated group showed a significant decrease
over OLETF rats (LETO; 0.54±0.05, OLETF; 1.10±0.15,
OLETFþ L158809; 0.71±0.10, Po0.05) (Figure 4d).
Effect of L158809 on renal lipid metabolism in experimental
animals
As L158809 improves albuminuria and glomerulosclerosis asso-
ciated with improvement in systemic metabolic abnormalities,
Table 1 | Biochemical parameters in experimental animals
LETO OLETF OLETF+L158809
Body weight (g) 516.6±28.8 640.0±22.4* 591.7±58.4*
Kidney/BW/103 0.33±0.05 0.36±0.01* 0.38±0.03*
FPG (mg/100 ml) 108±11.2 134.7±20** 126.3±8.7*,#
P-insulin (ng/ml) 1.32±0.24 2.48±0.45* 2.40±0.21*
P-c-peptide (pM) 655±57 4754±566** 4495±612**
P-Cr (mg/100 ml) 0.64±0.04 0.60±0.11 0.59±0.17
UV (ml/day) 17.6±10.5 16.1±4.43 17.5±4.7
UAE (mg/mgCr/day) 2.48±1.5 144.3±22.8*** 49.7±11.4**,##
UAE (mg/day) 12.1±3.4 443.3±28.4*** 116.5±21.8**,##
SBP (mm Hg) 120.5±18.4 146.5±19.2** 119.8±17.7#
Kid-Chol (mg/100 g) 273±37 486±65* 322±46#
Kid-TG (mg/100 g) 186±23 273±33* 201±27#
U-isopros (ng/day) 47.3±11.2 112.4±21.2* 67.3±18.9#
Fat-lipid
hydroperoxide
(nmol/mg)
12.3±2.33 31.8±11.9** 18.3±3.1#
BW, body weight; fat-lipid hydroperoxide, lipid peroxidation (hydroperoxide) in
adipose tissue (nmol per mg protein); FPG, fasting plasma glucose; Kid-Chol, total
cholesterol content in kidney (mg/100lg tissue); Kid-TG, triglyceride content in
kidney (mg/100lg tissue); P-c-peptide, plasma c-peptide concentration; P-Cr, plasma
creatinine concentration; P-insulin, plasma insulin concentration; SBP, systolic blood
pressure; UAE, urinary albumin excretion; U-isopros, 24lh urinary excretion of
8-isoprostane; UV, urine volume.
Values are expressed as mean±s.e.m.
*Po0.05, LETO vs OLETF and OLETF+L158809; **Po0.01, LETO vs OLETF and
OLETF+L158809; ***Po0.001, LETO vs OLETF; #Po0.05, OLETF vs OLETF+L158809;
##Po0.01, OLETF vs OLETF+L158809.
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Figure 1 | Glucose tolerance test in experimental animals.
L158809 group was treated for 6 months with L158809. Data are
shown as the mean±s.e.m. *Po0.05, LETO vs OLETF; #Po0.05,
OLETF vs OLETF with L158809.
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we next examined whether improvement of renal function
was derived from correction of alteration of renal lipid
metabolism. We measured the mRNA expression levels of the
molecules that are involved in lipid synthesis and cholesterol
efflux. As shown in Figure 5, mRNA expression of 3-hydroxy-
3-methylglutaryl-coenzyme A reductase, sterol-regulatory
element-binding protein-1c, and acetyl-coenzyme A carbox-
ylase were significantly increased in diabetic OLETF rats
compared with LETO rats, however ATP-binding cassette
transporter-1 that modulates cholesterol efflux was decreased
in OLETF rats. Interestingly, AT1 receptor antagonist
significantly decreased the gene expression of lipid synthesis
and increased the gene expression that modulates cholesterol
efflux. In accordance with these changes, renal cholesterol
and triglyceride contents were significantly decreased in
L158809-treated groups (Table 1). Furthermore, urinary
excretion of 8-isoprostane, which is an oxidative stress
marker, was significantly decreased in AT1 receptor antago-
nist treatment group (Table 1).
Effect of L158809 on lipid peroxidation and adipocytokine
gene expression from adipose tissue in experimental animals
The insulin resistance state and phenotypic change of adipo-
cytes in OLETF rats was associated with a 3.5-fold increase
in MCP-1 mRNA expression compared with LETO rats.
L158809 treatment significantly decreased MCP-1 gene ex-
pression (LETO; 1.00±0.24, OLETF; 3.45±0.45, OLETFþ
L158809; 2.21±0.21, Po0.05) (Figure 6a). In addition, adipo-
nectin gene expression was also significantly upregulated by
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Figure 3 | Representative renal histological findings in
experimental animals. (a) LETO rat at 46 weeks of age. (b) OLETF
rat at 46 weeks of age. (c) OLETF rat treated with L158809 for
6 months at 46 weeks of age. (d) Glomerulosclerosis index in
each group. Original magnification  100; Periodic Acid-Schiff
stain. Data are shown as the mean±s.e.m. ***Po0.001,
LETO vs OLETF; #Po0.05, OLETF vs OLETF with L158809.
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Figure 2 | Effects of L158809 on metabolic parameters in
experimental animals. L158809 was administered for 6 months
in OLETF rats, and various metabolic parameters were measured.
(a) Plasma lipid concentration. (b) Plasma adiponectin
concentration. (c) HOMA-IR. Data are shown as mean±s.e.
HOMA-IR was calculated using fasting glucose (mmol/l) fasting
insulin (mU/l)/22.5; *Po0.05, LETO vs OLETF, **Po0.01, LETO vs
OLETF, #Po0.05, OLETF vs OLETF with L158809.
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L158809
Figure 4 | Representative histological findings of epididymal
fat pads in experimental animals. (a) LETO rat at 46 weeks of
age. (b) OLETF rat at 46 weeks of age. (c) OLETF rat treated with
L158809 for 6 months at 46 weeks of age. (d) Epididymal fat mass
in each group. Original magnification  200; hematoxylin-and-
eosin stain. Data are shown as the mean±s.e.m. **Po0.01, LETO
vs OLETF; #Po0.05, OLETF vs OLETF with L158809.
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L158809 treatment in the adipose tissues (Figure 6b),
which is in agreement with significantly increased plasma
levels of adiponectin (LETO; 1.00±0.20, OLETF; 0.55±
0.14, OLETFþ L158809; 1.20±0.21, Po0.05) (Figure 2b).
Furthermore, lipid peroxidation of adipose tissue, which is
an oxidative stress marker, was significantly increased in
diabetic OLETF rats compared with LETO rats, and L158809
treatment showed significantly decreased levels of lipid
peroxidation (Table 1).
Effect of AT2 and angiotensin receptor antagonist on
adipocyte differentiation
Before the in vitro experiment, the duration of incubation
time was determined with stimulation by the addition of a
hormonal cocktail to reach the maximal differentiation state.
The degree of differentiation was evaluated by oil red O
staining and measurement of intracytoplasmic triglyceride
concentration. Full maturation of adipocytes was obtained
after 15 days of incubation. As a result, all in vitro experi-
ments were performed using adipocytes that had undergone
15 days of differentiation. High glucose stimuli induced a
slightly decreased adipocyte differentiation, whereas AT2
resulted in a dramatic inhibition of adipocyte differentiation
despite concomitant stimulation with the hormonal cocktail
(Figure 7a–f). In contrast with stimulation with AT2, AT1
receptor blockade and AT2 receptor blockade restored the
adipocytes to the differentiated form containing increased
cytoplasmic lipid accumulation (Figure 7a–f). As expected,
pioglitazone treatment significantly increased the differen-
tiated adipocytes. In accordance with the lipid accumulation,
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Figure 5 | mRNA expression for renal lipid metabolism in renal cortical tissues in experimental animals. (a) HMG-CoA reductase
gene expression; (b) ABCA1 gene expression; (c) ACC gene expression; (d) SREBP1c gene expression. Data are shown as the mean±s.e.m.
HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; ABCA1, ATP-binding cassette transporter-1; ACC, acetyl-coenzyme A
carboxylase; SREBP1c, sterol-regulatory element-binding protein-1c; *Po0.05, LETO vs OLETF; **Po0.01, LETO vs OLETF; #Po0.05,
OLETF vs OLETF with L158809, ##Po0.01, OLETF vs OLETF with L158809.
5
4
3
2
1
0
M
CP
-1
 m
RN
A 
ex
pr
es
sio
n
(M
CP
-1/
β-a
ct
in
)
**
#
#
LETO OLETF OLETF+L158809 LETO OLETF OLETF+L158809
Ad
ip
on
ec
tin
 m
RN
A 
ex
pr
es
sio
n
(A
 di
po
ne
cti
n/β
-
a
ct
in
)
1.4
1.6
1.2
1.0
0.8
0.6
0.4
0.2
0.0
*
Figure 6 | mRNA expression for MCP-1 and adiponectin in epididymal fat pads in experimental animals at 46 weeks of age.
(a) MCP-1 gene expression. (b) Adiponectin gene expression. Data are shown as the mean±s.e.m. *Po0.05, LETO vs OLETF; **Po0.01, LETO
vs OLETF; #Po0.05, OLETF vs OLETF with L158809.
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intracytoplasmic triglyceride levels were significantly de-
creased after AT2 stimulation, whereas AT1 and AT2 receptor
blockades restored their level to control levels (control,
100±10; high glucose, 92.3±12.3; AT2, 80.8±9.2;
AT2þAT1 blocker, 93.2±10.2; AT2þAT2 blocker,
97.4±8.2; pioglitazone, 110.5±14.3) (Figure 7g).
Effect of AT2 on 2-DOG uptake in cultured adipocytes
To evaluate the direct effect of AT2 on insulin sensitivity,
glucose uptake occurring in adipocytes was deter-
mined using a 2-deoxy-D-glucose (2-DOG) uptake assay.
First, the time course of 2-DOG uptake in adipocytes treated
with 100 nM of AT2 was examined. As shown in Figure 8a,
AT2 treatment prevented insulin-induced 2-DOG uptake in
adipocytes by approximately twofold, with a maximal
inhibition at 20 min. Interestingly, previous treatment with
L158809 significantly restored insulin-induced glucose up-
take. Furthermore, the inhibitory effect of 2-DOG uptake by
AT2 showed a dose-dependent fashion from 1 nM and
reached a maximal inhibition at 100 nM (Figure 8b).
Effect of AT2 and angiotensin receptor antagonist on
adipocytokine synthesis in cultured adipocytes
Next, this study examined whether phenotypic changes in
adipocytes are accompanied by a change in adipocytokine
synthesis. In line with the results of the oil red O stain and
intracytoplasmic triglyceride concentration measurements,
the peroxisome proliferator-activated receptor-g gene, which
is a differentiation marker in the adipocyte, also showed a
respective decrease and increase in expression after treatment
with AT2 and their antagonist (Figure 9a). Expression of
adiponectin, an important adipocytokine related to increased
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Figure 7 | Effects of high glucose, AT2, and AT receptor antagonist on adipocyte differentiation in cultured adipocytes.
Oil red O stain: (a) control; (b) high glucose medium; (c) AT2; (d) AT2 with AT1 receptor antagonist; (e) AT2 with AT2 receptor antagonist;
(f) pioglitazone. (g) The relative lipid contents in each condition. Differentiated adipocytes were treated for 24 h with 30 mM of glucose,
100 nM of AT2, 10mM of L158809 (AT1R blocker), 10 mM of PD-1233319 (AT2R blocker). As a positive control, pioglitazone and TNF-a were
administered at final concentrations of 10 mM and 10 ng/ml, respectively, to the culture media. The level of lipid accumulation in each
condition was corrected by that in the control cells without stimulation. Data are shown as the mean±s.e.m. AT1B, AT1 receptor blockade;
AT2B, AT2 receptor blockade; *Po0.05, ***Po0.001 vs controls; ##Po0.01, ###Po0.001 vs AT2.
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Figure 8 | Effect of AT2 and AT1 antagonist on 2-DOG uptake in adipocytes. (a) 2-DOG uptake in differentiated
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insulin sensitivity, was decreased after AT2 stimulation.
Although AT2 receptor blockade had no effect on adipo-
nectin expression, AT1 receptor blockade significantly
increased its expression (Figure 9b). Interestingly, MCP-1
expression was increased under high glucose stimulation
compared with the controls. AT2 stimulation resulted in a
more increase in MCP-1 expression, whereas AT1 and AT2
receptor blockades significantly decreased AT2-induced
MCP-1 overexpression (Figure 9c). PAI-1 expression also
showed a similar change to that of MCP-1, becoming
increased after AT2 stimulation and completely suppressed
with its receptor blockade (Figure 9d).
Effect of AT2 and angiotensin receptor antagonist on the
transcriptional activity of NF-jB, 8-isoprostane, and MCP-1
protein secretion in cultured adipocytes
As high glucose and AT2 stimulation upregulate MCP-1 gene
expression, we next evaluated whether MCP-1 protein
secretion is also increased with high glucose and AT2
stimulation and whether MCP-1 production is accompanied
with activation of the nuclear factor-kB (NF-kB) pathway.
Similar to gene expression, MCP-1 protein secretion was
significantly increased after high glucose and AT2 treatment.
Again, AT1 and AT2 receptor antagonists significantly
inhibited AT2-induced MCP-1 secretion (Figure 10a). Inter-
estingly, endogenous NF-kB transcriptional activity in
adipocytes was also increased to 25% after high glucose
stimulation and 28% after AT2 treatment, and the AT1
receptor antagonist significantly suppressed AT2-induced
NF-kB transcriptional activity (Figure 10b). To further
confirm the role of NF-kB activation by AT2 stimulation,
p65 western blotting was performed using extracted nuclear
proteins. As shown in Figure 10c, AT2 treatment increased
nuclear p65 protein expression, and the AT receptor
antagonist abolished its expression. In addition, to further
evaluate whether AT2-induced adipocytokine synthesis is
associated with oxidative stress, we next examined whether
AT2 increased oxidative stress in cultured adipocytes. As
shown in Figure 10d, both high glucose and AT2 significantly
increased 8-isoprosatne production, and L158809 signifi-
cantly suppressed its production.
DISCUSSION
This study first demonstrated that the AT receptor antagonist
improves insulin resistance through the modulation
of adipose tissue, including differentiation of adipocytes,
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Figure 9 | Effects of high glucose, AT2, and AT receptor antagonist on adipocytokine gene expression in cultured adipocytes.
(a) Peroxisome proliferator-activated receptor-g gene expression. (b) Adiponectin gene expression. (c) MCP-1 gene expression. (d) PAI-1
gene expression. Differentiated adipocytes were treated for 24 h with 30 mM of glucose, 100 nM of AT2, 10 mM of L158809 (AT1R blocker), and
10mM of PD-1233319 (AT2R blocker). As a positive control, pioglitazone and TNF-a were administered at a final concentration of 10 mM and
10 ng/ml, respectively, to the culture media. Data are shown as the mean±s.e.m. AT1B, AT1 receptor blockade; AT2B, AT2 receptor
blockade; *Po0.05, **Po0.01, ***Po0.001 vs controls; #Po0.05, ##Po0.01, ###Po0.001 vs AT2.
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leading to an improvement in adipocytokine synthesis in
type 2 diabetic rats. More importantly, evidence was found to
show that AT2 upregulates the proinflammatory molecules in
adipose tissue such as PAI-1, MCP-1, and NF-kB activation,
which was prevented by the AT receptor antagonist.
There is increasing evidence indicating that insulin
resistance is associated with systemic inflammation.13–16
Increased levels of inflammatory markers such as C-reactive
protein, IL-6, and PAI-1 relate to the incidence of type 2
diabetes, and multifactorial intervention in diabetic patients
reduces inflammatory markers.17 As one of the important
sources of systemic inflammation, adipose tissue has emerged
as an important player in this process, as adipocytes can
secrete a large number of cytokines and chemokines such as
TNF-a, IL-6, MCP-1, and adipocytokines, including leptin,
adiponectin, and resistin, and all of these molecules can exert
negative or positive effects on insulin resistance.18–20
In this study, it was found that plasma levels of
adiponectin and insulin were significantly decreased and
increased, respectively, in type 2 diabetic rats, and that these
changes were accompanied by lipid abnormalities. The
glucose intolerance state in diabetic rats was clearly
demonstrated by the glucose tolerance test; glucose levels
after an i.p. glucose injection showed markedly elevated levels
after two hours, compared with control rats. It is of interest
that the epididymal fat mass was significantly increased and
that the adipocytes in diabetic rats were larger, which are
more insulin-resistant phenotypes.21,22 In line with this
phenotypic change, MCP-1 gene expression was significantly
increased, and adiponectin expression was decreased in
diabetic rats. In this study, L158809 treatment significantly
decreased blood pressure, and it may be possible that blood
pressure-lowering effect may affect the synthesis of MCP-1
and adiponectin. However, our in vitro data clearly showed
that L158809 directly affects the synthesis of these cytokines
rather than the blood pressure-lowering effect.
In this study, L158809 treatment improved glycemic
control, increased plasma adiponectin levels, and resulted
in much better lipid profiles, including decreases in
cholesterol and triglyceride levels. However, there were no
significant changes in plasma insulin levels and HOMA-IR in
these overtly diabetic insulin-resistant rats. In this study, we
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Figure 10 | Effects of high glucose, AT2, and AT receptor antagonist on MCP-1 protein secretion, NF-jB activity,
and 8-isoprostane synthesis in cultured adipocytes. (a) Secretory MCP-1 protein was measured from culture supernatants by an enzyme-
linked immunosorbent assay method. MCP-1 content was corrected by the total cellular protein content. (b) Differentiated adipocytes
were cotransfected with an NF-kB promoter-driven luciferase vector and a TK-driving Renilla luciferase plasmid. Next, the cells were treated
for 24 h with 30 mM of glucose, 100 nM of AT2, 10 mM of L158809 (AT1R blocker), and 10 mM of PD-1233319 (AT2R blocker).
NF-kB reporter activity was normalized to Renilla luciferase activity. (c) Representative immunoblot using nuclear protein from cultured
cells for NF-kB p65. (d) 8-Isoprostane protein concentration was measured from cultured supernatant by an EIA method. 8-Isoprostane
levels were corrected by the total cellular protein content. Data are shown as mean±s.e.m. AT1B, AT1 receptor blockade; AT2B, AT2
receptor blockade; *Po0.05, **Po0.01, ***Po0.001 vs controls; #Po0.05, ##Po0.01, ###Po0.001 vs AT2.
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also evaluated the effect of AT2 receptor antagonist in OLETF
rats using PD123319, but we could not find any significant
effect in lipid profiles and metabolic parameters (data not
shown).
Another important finding in this study was that
phenotypic changes were observed in adipocytes after
treatment with L158809. Epididymal fat mass was signifi-
cantly decreased and L158809 treatment increased the
number of small, newly differentiated adipocytes, which are
known as a more insulin-sensitive phenotype than older,
large adipocytes.21,22 Furthermore, it was noted that these
phenotypic changes were accompanied by an improvement
in adipocytokine expression, such as downregulation of
MCP-1 expression and upregulation of adiponectin expres-
sion. Although macrophage infiltration was not observed in
adipose tissue, increased MCP-1 expression in adipose tissue
has recently been suggested as an important mediator in the
development of insulin resistance.23 On the other hand,
adiponectin has been considered as an anti-inflammatory
molecule, as adiponectin reduces the production of IL-6,
inhibits NF-kB activation, and inhibits the production of
endothelial adhesion molecules.24
This study further investigated the effect of the AT1
blockade on adipocyte function in cultured adipocytes to
define the molecular mechanism and direct the effects of RAS
inhibition in adipocytes. Interestingly, AT2 stimulation
inhibited the differentiation of adipocytes as measured by
oil red O staining and intracytoplasmic lipid concentration
measurements. In addition, the AT receptor antagonist
augments lipid accumulation and the differentiation of
adipocytes. Furthermore, adipocytokines such as peroxisome
proliferator-activated receptor-g and adiponectin, known to
increase insulin sensitivity, were significantly downregulated
by AT2, and the ARB inhibited these effects. On the contrary,
diabetogenic adipocytokines including MCP-1 and PAI-1
were induced by AT2 treatment, and again the AT receptor
antagonist also completely inhibited AT2-induced MCP-1
and PAI-1 expression. More importantly, our in vitro 2-DOG
uptake results clearly showed that AT2 significantly inhibited
insulin sensitivity and AT1 receptor antagonist restored
insulin sensitivity. Interestingly, high glucose stimuli also
directly upregulated MCP-1 and PAI-1 expression, although
there was no effect on antidiabetogenic adipocytokines.
These findings are in agreement with a previous report that
high glucose and advanced glycosylation end products
enhance the expression of PAI-1 in cultured adipocytes.25
As expected, the most dramatic effect on MCP-1 and PAI-1
expression was mediated by TNF-a stimulation, which has
been known as an inflammatory cytokine that mediates
insulin resistance.26
Recently, several studies have suggested potential mechan-
isms for the activation of inflammation in adipose tissue.27–29
Dietary fat and obesity increase the lipid content of
adipocytes, initiating a state of cellular stress, which is
accompanied by the activation of c-Jun N-terminal kinase
and NF-kB, leading to increased production of proinflam-
matory cytokines such as TNF-a, IL-6, MCP-1, and PAI-1.22
In this study, we could not observe any significant activation
of c-Jun N-terminal kinase (data not shown), and next we
performed another in vitro experiment to further confirm the
role of AT2 and AT receptor antagonist in the development
of insulin resistance by observing the direct effect of AT2 on
NF-kB activation in adipocytes. Interestingly, the NF-kB
reporter assays clearly showed that high glucose and AT2
activated endogenous NF-kB transcriptional activity in these
cells. The AT1 receptor antagonist significantly suppressed
AT2-induced NF-kB activation. In support of the role of
AT2 in the activation of NF-kB, Tsuchiya et al.30 and Skurk
et al.31 recently reported that AT2 induces MCP-1 and
IL-6 production by way of an NF-kB-dependent pathway in
cultured adipocytes. Taken together, the in vitro findings in
this study suggest that the AT1 receptor antagonist
contributes to the observed in vivo effects in insulin-resistant
diabetic rats by means of modulation of adipose tissue.
In this study, we also found that decreased albuminuria
and improvement in glomerulosclerosis was accompanied by
improvement in renal lipid metabolism by AT1 receptor
antagonist. In diabetic OLETF rats, mRNA expression levels
of elements involved in lipid synthesis such as 3-hydroxy-3-
methyl-glutaryl-coenzyme A reductase and sterol-regulatory
element binding protein-1c were significantly increased,
whereas ATP binding cassette transporter 1 that modulates
cholesterol efflux was decreased. Interestingly, AT1 receptor
antagonist induced improvement in alterations of renal lipid
metabolism and subsequently reduced renal cholesterol and
triglyceride contents. These results suggest that AT1 receptor
antagonist improves renal function via improvement in renal
lipid metabolic abnormalities.
The limitation in this study is that we used type 2 diabetic
rat model, which is already in a diabetic state associated with
insulin resistance instead of classical animal model of insulin
resistance such as high fat diet-induced model. More in vivo
studies using classical model of insulin resistance are
necessary to further define the protective role of AT receptor
antagonist in the development of diabetes.
In conclusion, this study suggests that ARB treatment
improves the differentiation of adipocytes and the activation
of the inflammatory process in adipose tissue, accompanied
by an improvement in adipocytokine synthesis. The study
data suggest that ARB treatment improves insulin resistance
through the modulation of adipose tissues, leading to a
protective effect for the prevention of diabetes mellitus.
MATERIALS AND METHODS
Animal studies
Otsuka Long–Evans Tokushima Fatty rats supplied by the Tokush-
ima Research Institute (Otsuka Pharmaceutical Co., Tokyo, Japan)
were used as type 2 diabetic models. Age-matched male LETO rats
served as the genetic control for the OLETF rats. The rats at 20
weeks of age were divided into three groups (n¼ 6 per group).
Group 1 consisted of LETO control rats. Group 2 animals were
OLETF type 2 diabetes rats, and group 3 consisted of OLETF rats
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treated with 1.5 mg/kg of L158809 (Merck & Co. Inc, Rahway, NJ,
USA) mixed in drinking water for 6 months. Rats had free access to
rat food and tap water and were caged individually under a
controlled temperature (23±21C) and humidity (55±5%) envir-
onment with an artificial light cycle. Daily amounts of water intake
were checked at regular intervals to affirm the dose of the
administered drug. At the end of the study period, systolic blood
pressure was measured using tail-cuff plethysmography (LE 5001-
Pressure Meter, Letica SA, Barcelona, Spain). Plasma glucose levels
were measured by a glucose oxidase-based method, and creatinine
levels were determined by a modified Jaffe method.32 Plasma insulin
levels and plasma adiponectin levels were measured using an
enzyme-linked immunosorbent assay kit (Linco Research, St
Charles, MO, USA). Plasma c-peptide levels were measured using
an enzyme-linked immunosorbent assay kit (Shibayagi, Shibukawa,
Japan). HOMA-IR was calculated using fasting glucose (mmol/
l) fasting insulin (mU/l)/22.5. Plasma triglyceride and cholesterol
analyses were performed using a GPO-Trinder kit (Sigma, St Louis,
MO, USA). A GTT was performed to assess the insulin resistance state
in each group. GTT was performed following 8-hour fasting, and
blood samples were collected through the tail vein. Rats received 2 g
dextrose per kg body weight by i.p. injection for GTT, and blood
sampling was done to measure blood glucose levels at 0, 30, 60, 90,
and 120 min after glucose loading. To determine the urinary albumin
excretion, individual rats were caged in a metabolic cage and 24-h
urine was collected at the end of the study. The urinary albumin
concentration was determined by a competitive enzyme-linked
immunosorbent assay (Shibayagi, Shibukawa, Japan) and corrected
by urinary creatinine concentration. Rats were killed under anesthesia
by i.p. injection of sodium pentobarbital (50 mg/kg). Experiments
were conducted in accordance with the Korea University Guide for
Laboratory Animals.
Analysis of gene expression by real-time quantitative PCR
in tissues and cells
Total RNA was extracted from epididymal fat tissues, renal cortical
tissues, or experimental cells with Trizol reagent and further purified
using an RNeasy Mini kit (Qiagen, Valencia, CA, USA). Primers
were designed from the respective gene sequences using Primer 3
software, and the secondary structures of templates were examined
and excluded using the mfold software program. Table 2 shows the
nucleotide sequences of the primers. Quantitative gene expression
was performed on a LightCycler 1.5 system (Roche Diagnostics
Corporation, Indianapolis, IN, USA) using SYBR Green technology.
Real-time reverse transcription-PCR was performed for 10 min at
50 1C and 5 min at 95 1C. Subsequently, 45 cycles were applied,
consisting of denaturation for 10 s at 95 1C and annealing with
extension for 30 s at 60 1C. At the end of the PCR cycle, samples
were heated to 95 1C to check that a single PCR product was
obtained. The ratio of each gene and b-actin level (relative gene
expression number) was calculated by subtracting the threshold
cycle number (Ct) of the target gene from that of b-actin and raising
2 to the power of this difference.
Histological examination of adipose tissue and kidney
The adipose tissue obtained from epididymal fat was fixed for 48 h
with 10% paraformaldehyde at 4 1C, dehydrated, embedded in
paraffin, and cut into 4-mm-thick slices, and stained with
hematoxylin and eosin and observed under a microscope to
compare adipocyte sizes. The kidney tissues embedded in paraffin
were cut into 4-mm-thick slices and were stained with Periodic
Acid-Schiff. A semiquantitative score (SI) was used to evaluate the
degree of glomerulosclerosis on Periodic Acid-Schiff-stained sec-
tions according to the method described by Ma et al.33 The severity
of sclerosis for each glomerulus was graded from 0 to 4þ as follows:
0, no lesion; 1þ , sclerosis of o25% of the glomerulus; 2þ , 3þ ,
and 4þ , sclerosis of 25–50, 450–75, and 475% of the glomerulus,
respectively. All histological examinations were carried out by a
pathologist in a blinded manner, and more than 80 glomeruli were
analyzed in kidney sections from each rat.
Lipid extraction and measurement of lipids from renal tissues
Lipids from renal cortical tissues were extracted by the method of
Bligh and Dyer.34 Total cholesterol and triglyceride content was
measured using commercial kit (Wako Chemicals, Richmond, VA,
USA) according to the manufacturer’s instructions.
Measurement of 8-isoprostane from urine and cultured
adipocytes
8-Isoprostane in either 24 h urine or culture supernatant from
adipocytes was measured using EIA kit (Cayman Chemical, Ann
Arbor, MI, USA). For measurement of 8-isoprostane from culture
supernatant, differentiated adipocytes were serum-starved for 24 h,
then treated with 30 mM of high glucose. To study the effect of AT2,
adipocytes were treated with or without AT2 at a final concentration
Table 2 | Primer sequences for real-time quantitative PCR
Target gene Primer sequence (50 to 30)
Amplicon
length
(bp)
Rat MCP-1, forward CACCTGCTGCTACTCATTCACT 415
Rat MCP-1, reverse GTTCTCTGTCATACTGGTCACTTCT
Rat adiponectin, forward TAATCCTGCCCAGTCATGAAG 216
Rat adiponectin, reverse CATCTCCTGGGTCACCCTTA
Rat HMG-CoA, forward GTGCCCAAAATTTGAAGAGG 104
Rat HMG-CoA, reverse GCAGGTTCTGGAACTGGAAG
Rat ABCA1, forward TGCTTCCGTTATCCAACTCC 79
Rat ABCA1, reverse AGAATAGGCGGGACACAATG
Rat ACC, forward GGTGAAGAGAGGCCGTGA 75
Rat ACC, reverse ACAAATTCGGCTGGGGAAG
Rat SREBP1c, forward TGTGGAGCTCAAGGACCTG 98
Rat SREBP1c, reverse TGTGCTGTAAGAAGCGGATG
Rat b-actin, forward GCGCAAGTACTCTGTGTGGA 89
Rat b-actin, reverse CATCGTACTCCTGCTTGCTG
Mouse PPARg, forward AGACCACTCGCATTCCTTTGACAT 271
Mouse PPARg, reverse TCCCCACAGACTCGGCACTCAATG
Mouse adiponectin,
forward
TGTTGGAATGACAGGAGCTGAA 121
Mouse adiponectin,
reverse
CACACTGAAGCCTGAGCGATAC
Mouse MCP-1, forward CTGGATCGGAACCAAATGAG 95
Mouse MCP-1, reverse CGGGTCAACTTCACATTCAA
Mouse PAI-1, forward TCCTCATCCTGCCTAAGTTCTC 365
Mouse PAI-1, reverse GTGCCGCTCTCGTTTACCTC
Mouse b-actin, forward GGACTCCTATGTGGGTGACG 118
Mouse b-actin, reverse CTTCTCCATGTCGTCCCAGT
ABCA1, ATP-binding cassette transporter-1; ACC, acetyl-coenzyme A carboxylase;
HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; MCP-1, monocyte
chemoattractant peptide-1; PAI-1, plasminogen activator inhibitor-1; PPARg,
peroxisome proliferator-activated receptor-g; SREBP1c, sterol regulatory element-
binding protein-1c.
In this experiment, each sample was run in triplicate, and the corresponding
nonreverse transcribed mRNA sample was used as a negative control. The mRNA
level of each sample was normalized to that of b-actin mRNA.
898 Kidney International (2008) 74, 890–900
o r i g i n a l a r t i c l e MH Lee et al.: Angiotensin receptor antagonist and insulin resistance
of 100 nM. In some wells, L158809 or PD-1233319 was pretreated
30 min before stimulation with AT2. All experimental groups were
cultured in triplicate and harvested at 24 h, and conditioned media
were collected at the end of the treatment period.
Measurement of lipid peroxidation from adipose tissue in
experimental animals
The extent of the peroxidative reaction in the adipose tissue was
determined by measuring lipid hydroperoxides directly utilizing
the redox reactions with ferrous ions from adipose tissue homo-
genates using lipid hydroperoxide (LPO) assay kit (Cayman
Chemical, Ann Arbor, MI, USA).
Culture and differentiation of adipocytes
3T3-L1 cells were obtained from American Type Cell Culture
(ATCC, Manassas, VA, USA) and were maintained in Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine serum and
100 U/ml antibiotics at 37 1C under a humidified 5% CO2 atmo-
sphere. Cultures were fed every 2–3 days during growth and every 2
days after confluence. Differentiation of pre-adipocytes into
adipocytes was induced by the addition of a hormone cocktail as
described previously.35 In brief, 2 days after confluence, the medium
was removed and replaced with standard adipocyte differentiation
induction medium containing 0.5 mmol/l isobutylmethylxanthine,
1 mmol/l dexamethasone, and 10 mg/ml insulin. Three days later, the
induction medium was replaced by Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum plus insulin only, and cells
were then fed every 2–3 days. Differentiation of adipocytes was
confirmed morphologically by multiple oil red O-stained lipid
droplets in the cytoplasm and quantitation of intracytoplasmic
lipids (see below). As full maturation of adipocytes occurs 15 days
after differentiation, all in vitro experiments were performed using
cells 15 days after differentiation. To evaluate the effects of AT2, ATI
and AT2 receptor (AT1R and AT2R, respectively) blockers, and high
glucose conditions on adipocyte function, cells were treated for 24 h
with AT2 at a final concentration of 100 nM, 10 mM of L158809
(AT1R blocker), 10 mM of PD-1233319 (AT2R blocker), and 30 mM
of glucose. As a positive control, pioglitazone (Takeda Pharmaceu-
tical Co., Osaka, Japan) and TNF-a were administered at final
concentrations of 10 mM and 10 ng/ml, respectively, to the culture
media.
Quantitation of intracytoplasmic triglyceride levels
After being induced for 15 days, adipocytes were treated under
different conditions for 48 h and then the cells were monitored by
measurement of intracellular lipid accumulation using Oil red O
staining as described previously.36 The cells were fixed with 3%
glutaraldehyde for 1.5 h, and then the fixation solution was replaced
by 500 ml of 60% isopropyl alcohol. After 5 min, isopropyl alcohol
was evaporated, and the adipocytes were stained in a working
solution of 300 ml oil Red O for 2 h. The stain solution was removed,
and the cells were rinsed in 500 ml of 60% isopropyl alcohol for 5 s.
To extract the dye, 700 ml of 60% isopropyl alcohol was added per
well and then sealed plates were shaken for 2 h. The extracted dye
was then quantitated spectrophotometrically at 510 nm. The level of
lipid accumulation in each stimuli condition was corrected by that
found in the control cells without stimulation. All experimental
groups were cultured in triplicate and harvested at 24 h for the
extraction of total RNA and protein. For the measurement of
secreted MCP-1 in the cultured medium, conditioned media were
collected at the end of the treatment period and measured by a
quantitative sandwich enzyme-linked immunosorbent assay using a
commercial kit (Biosource Inc., Camarillo, CA, USA).
Measurement of glucose uptake in cultured adipocytes
We next performed 2-DOG uptake assay to define the direct effect of
AT1 receptor antagonist on insulin sensitivity in adipocytes.
Differentiated adipocytes were starved in serum-free medium for
24 h and then washed three times with PBS buffer. Cells were
incubated in 1 ml of Krebs–Ringer phosphate HEPES (KRPH) buffer
(136 mM NaCl, 4.7 mM KCl, 1.2 mM CaCl2, 2.5 mM Na2HPO4, 10 mM
HEPES and 0.1% (w/v) bovine serum albumin, pH 7.4) for 30 min
at 37 1C. The cells were then stimulated with 100 nM of insulin with
or without 100 nM of AT2 and incubated for 15 min at 37 1C. Cells
were next incubated with 1 mCi of 2-deoxy-[1-3H]-D-glucose and
incubated for the indicated times from 10 to 30 min. To exclude
noncarrier-mediated glucose uptake, 10mM of cytochalasin B was
pretreated for 30 min in control wells. In some wells, L158809 was
administered 30 min before treatment with AT2. At the indicated
time, the media was collected, cells washed three times with PBS
buffer and lysed in 0.1 N NaOH for 1 h at room temperature. Total
radioactivity from media (Rm) and total cell-associated radioactivity
from lysates (Rc) were counted using a liquid scintillation counter. True
glucose uptake was calculated as follows: radioactivity of glucose
uptake¼ [R(c)/(R(m)þR(c))]sample[R(c)/(R(m)þR(c))]cytochalasin B.
The radioactivity was normalized for total protein quantified by the
Bradford method. Next, the dose dependency of AT2 in glucose
uptake was determined. As peak inhibition of glucose uptake
occurred at 20 min, different concentrations of AT2 at final
concentrations of 1, 10, and 100 nM were treated for 20 min, and
glucose uptake was measured as described previously.
Transient transfection and luciferase reporter activity assay
To test the effect of high glucose stimuli, AT2, and their antagonist
on NF-kB transcriptional activity in adipocytes, a luciferase reporter
assay was performed. An NF-kB reporter plasmid containing
three NFkB consensus sequences was provided by Dr Timothy
Blackwell.37 Cells were plated onto 24-well plates at a density of
1 105 cells/well. Following 24 h of growth, the cells were trans-
fected with 1 mg of NF-kB reporter plasmid and 1 mg of plasmid
containing Renilla luciferase driven by a TK promoter for 24 h using
Superfect (Qiagen, Valencia, CA, USA). After that, cells were treated
for 24 h with 100 nM of AT2, 10 mM of L158809, 10 mM of PD-
1233319, and 30 mM of glucose. In some wells, pioglitazone and
TNF-a were administered at a final concentration of 10 mM and
10 ng/ml, respectively. After 24 h, luciferase activity was determined
using the dual luciferase assay system according to the manufac-
turer’s instructions (Promega Corp., Madison, WI, USA). To control
for differences in transfection efficiency, a plasmid containing
Renilla luciferase was included in each transfection and used for
normalization.
Extraction of nuclear proteins and western blotting
Nuclear proteins from cells were extracted using a commercial
nuclear extraction kit according to the manufacturer’s instructions
(Active Motif, Carlsbad, CA, USA). The protein concentration was
determined using the bicinchoninic acid method (Pierce Pharma-
ceuticals, Rockford, IL, USA). Twenty micrograms of protein were
electrophoresed on 10% SDS–polyacrylamide gel electrophoresis
mini-gel under denaturing conditions. The proteins were transferred
onto a polyvinylidene difluoride membrane (Immobilon-P, Milli-
pore, Bedford, MA, USA) over 150 min at 250 mA. After incubating
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the membranes with blocking solution for 1 h at room temperature,
the membranes were hybridized with rabbit polyclonal anti-p65
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
diluted 1:1000 in blocking buffer overnight at 4 1C. The filter was
then incubated with horseradish peroxidase-conjugated secondary
antibody, diluted 1:1000, for 60 min at room temperature. The
detection of specific signals was performed using the enhanced
chemiluminescence method (Amersham, Buckinghamshire, UK).
Equal amounts of protein loading were confirmed by b-actin
western staining of the gel.
Statistical analysis
Nonparametric analysis was used due to the relatively small number
of samples present (animal experiment was six in each group and
in vitro experiment was three in each condition). Results were
expressed as the mean±s.e.m. A Kruskall–Wallis test was used for
comparison of more than two groups, followed by a Mann–Whitney
U-test for comparison using a microcomputer-assisted program
with SPSS for Windows 10.0 (Spss Inc., Chicago, IL, USA).
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